Your Manual Operating Model Is Now Your Biggest Risk
Life sciences organizations are under pressure to move faster, reduce compliance cost, and strengthen inspection readiness — without proportional increases in headcount.
Meanwhile, AI capabilities are already embedded inside the platforms you own. The question isn’t whether to adopt AI. It’s whether you’re activating what’s already available — responsibly, defensibly, and at scale.
This white paper maps 47 concrete AI use cases across eight regulated domains, with quantified outcomes and inspection-aware architecture — so you can move from pilot to production with confidence.
Download the White Paper >>>
What’s Inside
- 47 use cases across 8 functional domains: Quality, Regulatory, Clinical, Manufacturing, Safety & PV, Medical Affairs, Cybersecurity, and Corporate Functions
- Quantified outcomes: cycle time reductions of 30–80% depending on domain, achieved without linear headcount growth
- AI maturity progression: from assistive automation to generative reasoning to predictive intelligence
- Inspection-ready architecture: multi-agent system designs with human-in-the-loop governance and full audit trails
- Buy vs. Build vs. Augment: framework for evaluating platform-embedded AI vs. custom development
- 6 deep dives: inspection readiness, batch record review by exception, TMF quality intelligence, labeling impact analysis, case processing, and MLR review
Who This Is For
- Quality & Compliance: CQOs, VPs of Quality managing deviations, CAPAs, and inspection readiness
- Regulatory Affairs: VPs of RA navigating submission complexity and labeling
- Clinical Operations: VPs of Clinical Ops overseeing TMF and CRO performance
- Manufacturing & Supply Chain: SVPs of Ops tackling batch review and supply disruption
- Safety & Pharmacovigilance: Heads of PV facing 8–12% annual case volume growth
- Medical Affairs: Leaders managing MLR cycles averaging 4–6 weeks with 30%+ rework
- CIOs, CTOs & Chief AI Officers: Evaluating AI through the lens of operational impact
The Numbers That Matter
| Domain | Impact |
|---|---|
| Quality | 30–50% faster deviation triage |
| Manufacturing | 50–80% reduction in batch record review |
| Safety & PV | 50–70% reduction in narrative drafting |
| Regulatory | 20–35% faster submission readiness |
| Medical Affairs | 25–35% reduction in MLR review cycle time |
| Clinical | 30–50% reduction in manual TMF QC |
Why USDM
USDM Life Sciences partners with regulated organizations to embed intelligent automation into existing enterprise platforms — reducing compliance cost, accelerating execution, and remaining defensible under inspection.
Contributors include USDM’s Chief AI Officer, VP of Strategy & Operations, VP of Delivery Operations, Head of Cybersecurity Services, and senior domain consultants.
Contributors to this White Paper include:
- Jennell Botero, Principal Consultant
- Hovsep Kirikain, Vice President of Strategy and Operations
- Mark Ohrvall, Vice President of Delivery Operations
- Lisa Om, Vice President of Marketing & Communications
- John Petrakis, Chief AI Officer
- Brian Rankin, Head of Cybersecurity Services
- Brittany Walker, Principal Consultant
Download the White Paper >>>
Watch the USDM Summit On-Demand
This white paper is part of a broader conversation on how life sciences organizations can move from AI intent to inspection-ready impact.
At the USDM Life Sciences Summit 2026, industry leaders, practitioners, and regulators explored these use cases in greater depth—sharing real-world lessons, architectural patterns, and governance approaches that work in regulated environments.
If this dossier resonates with your current challenges, the Summit is where strategy becomes execution.